How to read this guide
Keep population, endpoint, timepoint, comparator, source type, and limitation attached to every result. A group average is not an individual prediction.
01 / Definition
What is tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing factor (GHRF), also called growth hormone-releasing hormone (GHRH). It is not replacement growth hormone. Its mechanism is a pathway description, not a promise to “boost HGH,” change every body-composition measure, or produce a clinical benefit.
Tesamorelin
A synthetic signal analog in the growth-hormone-releasing pathway.
Pituitary GH
The pituitary responds by releasing growth hormone, within normal feedback systems.
IGF-1 / IGFBP-3
Downstream markers such as IGF-1 and IGFBP-3 can change and still require clinical context.
GHRF/GHRH → pituitary GH → downstream IGF-1/IGFBP-3 is useful pathway context. It does not establish general weight loss, liver treatment, cardiovascular benefit, anti-aging, or longevity outcomes.
02 / Label boundary
What the labeled indication actually covers.
The FDA-approved wording belongs to named EGRIFTA products, a defined population, and a defined endpoint. It should not be stretched into a general claim about tesamorelin, body weight, or another use.
EGRIFTA WR and EGRIFTA SV have a narrow U.S. indication for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
The products are not indicated for general weight-loss management, and the label says long-term cardiovascular safety has not been established.
A paper may study an investigational question outside the label. An unapproved, compounded, research, or supplier product is not automatically equivalent to an approved EGRIFTA product.
The EGRIFTA label context does not provide administration details here. Investigational research may ask different questions, and an unapproved or non-equivalent product does not inherit the approval of EGRIFTA WR or SV.
03 / Measurement primer
A fat compartment is not a clinical outcome.
Tesamorelin studies use different measures. Imaging and biomarkers can be useful intermediate endpoints, but a change in one measure is not automatically a patient-important benefit.
Visceral adipose tissue is fat inside the abdomen around internal organs. CT can quantify it, making it an imaging endpoint rather than a scale-based weight measure.
Subcutaneous adipose tissue is fat beneath the skin. A change in VAT can differ from a change in SAT, so the compartments should not be collapsed into one number.
A scale measures total mass. It does not identify how much change came from VAT, SAT, lean tissue, fluid, or other compartments.
Imaging estimates the proportion of fat in the liver. It is distinct from biopsy findings and does not by itself establish fibrosis change or fewer liver events.
These are liver-associated enzymes. A group-level change or association can inform a research question without proving liver treatment or outcome prevention.
Patient-important outcomes include complications, cardiovascular events, liver events, and mortality. Imaging and biomarkers do not automatically establish them.
04 / Pivotal randomized human evidence
The pivotal record, study by study.
These pivotal cards keep population, design, timeframe, endpoint, comparator, finding, and limitation together. They report group-level results from defined studies, not individual predictions.
Metabolic effects of a growth hormone-releasing factor in patients with HIV
- Population
- 412 adults with HIV and abdominal fat accumulation.
- Design
- Randomized, placebo-controlled trial.
- Timeframe
- 26 weeks.
- Endpoint
- CT-measured visceral adipose tissue (VAT), with metabolic measures.
- Comparator
- Tesamorelin versus placebo.
Reported finding: VAT decreased 15.2% with tesamorelin and increased 5.0% with placebo. Triglycerides and the total-cholesterol/HDL ratio improved, IGF-I increased, and there was no significant between-group glycemic difference reported.
Limitation: The selected cohort and short timeframe limit conclusions about long-term safety, durability, and clinical events. CT VAT and metabolic markers are not the same as patient-important outcomes.
Effect of tesamorelin on visceral fat and lipid profiles in HIV-infected patients with abdominal fat accumulation
- Population
- 404 adults in a randomized efficacy phase followed by an extension.
- Design
- Six-month randomized phase plus an extension; continued treatment and a switch to placebo were observed.
- Timeframe
- Six months, with approximately 12 months of continued-treatment follow-up.
- Endpoint
- VAT, body composition, IGF-1, and glucose context.
- Comparator
- At six months, tesamorelin versus placebo; extension observations included continued treatment and placebo switch.
Reported finding: At six months, VAT changed −10.9%/−21 cm² with tesamorelin versus −0.6%/−1 cm² with placebo. Continued treatment produced approximately an 18% VAT reduction over 12 months, while the VAT benefit was rapidly lost after switching to placebo.
Limitation: The extension is not a new randomized, multi-year trial. Its selected participants and discontinuation observation cannot establish long-term clinical benefit or safety.
05 / Other primary human evidence
Additional studies, kept in a separate tier.
These papers add extension, imaging, liver-fat, histology-related, and post hoc context. They should not be read as a single pooled result or as proof of a clinical liver outcome.
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
- Population
- People with HIV and abdominal fat accumulation continuing into a 52-week extension.
- Design
- Extension observation, not a new multi-year randomized trial.
- Timeframe
- 52-week extension, with observation after discontinuation.
- Endpoint
- VAT and triglycerides during continued treatment and after stopping.
- Comparator
- Within-extension continuation and post-discontinuation observation; no multi-year randomized comparator.
Reported finding: While treatment continued, the report described approximately an 18% VAT reduction and an approximately 51 mg/dL triglyceride decrease. VAT reaccumulated after discontinuation.
Limitation: An extension and post-discontinuation observation do not answer multi-year safety, cardiovascular events, or whether a change improves a clinical outcome.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
- Population
- 50 enrolled and 48 treated participants with HIV and abdominal fat accumulation.
- Design
- Small randomized clinical imaging study.
- Timeframe
- 6 months.
- Endpoint
- VAT and hepatic lipid-to-water ratio.
- Comparator
- Tesamorelin versus placebo.
Reported finding: VAT changed −34 cm² with tesamorelin versus +8 cm² with placebo. Median hepatic lipid-to-water change was −2.0% versus +0.9% with placebo.
Limitation: This small imaging study does not prove fibrosis reversal, prevention of liver events, or treatment of fatty liver as a clinical disease.
Tesamorelin reduces liver fat and improves liver histology in HIV-infected patients with nonalcoholic fatty liver disease
- Population
- 61 people with HIV and hepatic fat fraction at least 5%; 30 received tesamorelin and 30 placebo in the randomized comparison.
- Design
- Randomized 12-month phase followed by a 6-month open-label phase.
- Timeframe
- 12 months randomized, then 6 months open-label.
- Endpoint
- Hepatic fat fraction and histology-related measures.
- Comparator
- Tesamorelin versus placebo during the randomized phase.
Reported finding: The reported hepatic-fat treatment effect was −4.1 percentage points, a relative reduction of 37%; 35% versus 4% were below 5% hepatic fat fraction.
Limitation: The cohort was small and selected, and the study did not establish clinical liver outcomes such as fibrosis-related events, cirrhosis prevention, or survival.
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV
- Population
- Post hoc analysis of 806 phase 3 participants.
- Design
- Post hoc VAT-response analysis, not a new randomized liver-outcomes trial.
- Timeframe
- During the represented phase 3 study periods.
- Endpoint
- VAT response in relation to ALT and AST changes.
- Comparator
- VAT responders versus nonresponders.
Reported finding: VAT responders had larger ALT/AST reductions than nonresponders in the post hoc analysis.
Limitation: This is an association, not proof that VAT reduction treated liver disease or prevented liver events. It does not establish causation or clinical benefit.
06 / Safety and uncertainty
Label signals need product and timeframe context.
The current DailyMed EGRIFTA WR and SV labels are the controlling sources for the product-level safety language summarized here. This is context about the label, not personal monitoring advice, a safety verdict, or a treatment plan.
IGF-1 and glucose
Current EGRIFTA WR and SV labeling includes elevated IGF-1 and glucose intolerance or diabetes in its product-level safety context.
Fluid and musculoskeletal effects
The label describes fluid-retention and musculoskeletal effects. These statements belong to the labeled product context, not a personal monitoring plan.
Hypersensitivity and injection sites
Hypersensitivity reactions and injection-site reactions are part of the current label context.
Malignancy and critical illness
The label includes active-malignancy contraindication or warning context and a critical-illness warning. These are product-level safety boundaries.
Immunogenicity and evidence limits
Immunogenicity is described in the label. Pregnancy, pediatric, and older-adult evidence remain limited in the relevant product record.
Cardiovascular uncertainty
Long-term cardiovascular safety has not been established. A short study or surrogate change cannot fill that gap.
07 / Regulatory and product status
Approval belongs to the product and indication.
At the August 22, 2026 snapshot, current DailyMed records for EGRIFTA WR and EGRIFTA SV were checked, both carrying the narrow HIV-associated lipodystrophy indication. The WR record was updated July 29, 2026 with a label revised 3/2025; the SV record was updated July 29, 2026 with a label revised 2/2024.
The March 25, 2025 supplemental approval for BLA 022505/S-020 covered a new formulation, presentation, and manufacturing site. It did not create a general weight-loss, anti-aging, or longevity indication.
WR and SV are not substitutable according to the product labeling.
The original FDA approval record for NDA 022505 is dated November 10, 2010. The approval is product-specific and remains bounded by the labeled population and endpoint.
An investigational paper does not expand a label, and research, compounded, supplier, or other unapproved material is not automatically equivalent to EGRIFTA.
Current status should be rechecked whenever this guide is materially updated. Regulatory records, labels, and registry status can change independently of a paper’s publication date.
08 / Known versus unresolved
Keep supported findings beside the unanswered questions.
Supported in this record
A narrow, product-specific U.S. EGRIFTA indication exists for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.
Randomized HIV studies reported changes in CT- or MRI-derived VAT and selected lipid or hepatic-fat measures over defined periods.
Extension and discontinuation observations indicate that VAT can reaccumulate after tesamorelin is stopped.
Hepatic-fat, ALT, and AST findings remain surrogate or association evidence rather than established clinical liver outcomes.
Still unresolved
Long-term cardiovascular, malignancy, glucose, and retinopathy risks
Durability after discontinuation and the meaning of repeated extension observations
Liver histology, fibrosis, liver events, mortality, and survival
Generalizability beyond HIV-associated lipodystrophy
Anti-aging, general weight-loss, bodybuilding, muscle-building, performance, and longevity claims
09 / Reader checklist
Questions to carry into the next paper.
Identify the evidence tier: label, FDA letter, peer-reviewed paper, registry, or post hoc analysis.
Name the population, including the condition and relevant selection criteria.
Keep the comparator attached to every finding.
Check the endpoint and measurement method, such as CT VAT, MRI hepatic fat fraction, weight, ALT, or AST.
Keep the timeframe visible, including randomized phases, extensions, and open-label follow-up.
Check denominators, treated numbers, missing scans, and attrition before reading a percentage.
Separate VAT from SAT and total body weight.
Ask whether the endpoint is a surrogate or a clinical outcome.
Separate an association from a causal claim.
Distinguish label language from a paper, registry record, or company statement, then recheck current status whenever this guide is materially updated.
11 / Source trail
Follow the record directly.
The source trail separates regulatory labels, FDA approval letters, peer-reviewed papers, and ClinicalTrials.gov records. Registry records support study design and status; peer-reviewed papers support quantitative interpretation. Dates below identify the supplied cutoff or the source’s stated record date.
Regulatory labels
Direct links / datedFDA approval records
Direct links / datedPeer-reviewed papers
Direct links / datedFalutz et al., Metabolic effects of a growth hormone-releasing factor in patients with HIV
New England Journal of Medicine, 2007; PMID 18057338.
Falutz et al., Effect of tesamorelin on visceral fat and lipid profiles in HIV-infected patients with abdominal fat accumulation
JAIDS, 2010; PMID 20101189.
Falutz et al., Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
AIDS, 2008; PMID 18690162.
Stanley et al., Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
JAMA, 2014; PMID 25038357.
Stanley et al., Tesamorelin reduces liver fat and improves liver histology in HIV-infected patients with nonalcoholic fatty liver disease
Lancet HIV, 2019; PMID 31611038.
Fourman et al., Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV
AIDS, 2017; PMID 28832410.
ClinicalTrials.gov records
Direct links / dated12 / Closing disclosure
Keep the boundary visible.
Axiolume reviewed this guide for source coverage, evidence boundaries, and disclosures. This is general health education, not medical advice, treatment guidance, a personal-use recommendation, medical or legal review, peer review, or regulatory approval. The August 22, 2026 status snapshot should be rechecked whenever the guide is materially updated.
Axiolume provides general health education. It does not provide medical advice, diagnosis, dosing, protocols, treatment recommendations, injections, reconstitution, sourcing, or individualized guidance. It does not encourage personal use of tesamorelin or imply that EGRIFTA approval applies to other products or uses.